Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
February 22, 2022 07:30 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
February 17, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
February 16, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
January 25, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
January 03, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 16, 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 16:18 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter...
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
November 03, 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
October 27, 2021 07:30 ET
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
October 12, 2021 07:30 ET
|
Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...